Etoposide (VP-16)
Epidemiology
- Indications
- Non-small Cell Lung Cancer
- Small Cell Lung Cancer
Pharmacology
- Podophyllotoxin agent
- Topoisomerase-II inhibitor
Clinical Presentations
- Acute Lung Injury-ARDS (see Acute Lung Injury-ARDS)
- Epidemiology
- Only a few reported cases
- Synergistic Toxicity with Methotrexate (see Methotrexate): etoposide increases intracellular methotrexate levels
- Diagnosis
- OLB: alveolar edema, diffuse alveolar damage, atypical type II pneumocytes
- Clinical: onset shortly after first round of etoposide or after prolonged treatment
- Treatment/Prognosis: withdrawal of drug + corticosteroids -> variable response
References